Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5530166 | 1.00 | MAPT (0.55) | MAPTHDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL9063455 | 0.86 | MAPT (0.50) | MAPTHDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL3426260 | 0.84 | ACACB (0.64) | MAPTALDH1A1HTTHPGDLMNA | |
| SCHEMBL11749030 | 0.84 | MAPT (0.49) | MAPTHDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL5044206 | 0.84 | MAPT (0.49) | MAPTHDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL27773043 | 0.83 | HSD17B10 (0.53) | MAPTALDH1A1KDM4EHSD17B10HTT | |
| SCHEMBL27676416 | 0.82 | HTT (0.44) | MAPTHDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL27676419 | 0.82 | HTT (0.44) | MAPTHDAC3HDAC4HDAC1HDAC6 | |
| Zinc Ion SCHEMBL2921239 | 0.81 | MAPT (0.47) | MAPTHDAC3HDAC4HDAC1HDAC6 | |
| SCHEMBL28527565 | 0.81 | HSD17B10 (0.52) | MAPTHDAC6ALDH1A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611109-A4 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO LTD (JP) | 2009-06-24 | — | — | EP | claimed |
| JP-2006522109-A | — | — | 2006-09-28 | — | — | JP | claimed |
| EP-1611109-A1 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-01-04 | — | — | EP | claimed |
| WO-2004087680-A1 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-10-14 | — | — | WO | claimed |
| US-4177072-A | HYDROPHILIC AND OLEOPHILIC AREAS | FUJI PHOTO FILM CO., LTD. (JP) | 1979-12-04 | — | — | US | claimed |
| US-20240091386-A1 | COMPOSITIONS, METHODS, MODELS AND USES FOR SIMIAN VARICELLA VIRUS (SVV) CHIMERIC CONSTRUCTS IN HUMAN HEALTH CONDITIONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2024-03-21 | — | — | US | disclosed |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20060173096-A1 | Aqueous ink composition, and ink jet recording method and recorded matter using the same | SEIKO EPSON CORPORATION | 2006-08-03 | — | — | US | disclosed |
| US-6586450-B2 | E.g., (2-(4-methoxyphenethyl))-N'-(2-(5-bromopyridyl))-thiourea; enzyme inhibitors of reverse transcriptase; viricides for HIV infection, including mutant, drug-sensitive, drug and multi-drug resistance strains | PARKER HUGHES INSTITUTE | 2003-07-01 | — | — | US | disclosed |
| US-6407246-B2 | REVERSE TRANSCRIPTASE INHIBITORS TO TREAT HIV | PARKER HUGHES INSTITUTE | 2002-06-18 | — | — | US | disclosed |
| EP-1194406-A1 | PHENETYL-THIOUREA COMPOUNDS FOR TREATING HIV INFECTIONS | Parker Hughes Institute (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6362228-B2 | CYCLOALKY OR HETEROCYCLIC SUBSTITUTED PHENETHYL-THIOUREA COMPOUNDS USED AS INHIBITOR OF REVERSE TRANSCRIPTASE AND EFFECTIVE AGENTS FOR HIV INFECTION TREATMENT, INCLUDING MUTANT, DRUG SENSITIVE OR DRUG RESISTANT STRAINS OF HIV | PARKER HUGHES INSTITUTE | 2002-03-26 | — | — | US | disclosed |
| US-20020028837-A1 | Phenethyl-thiourea compounds and use | WAYNE HUGHES INSTITUTE | 2002-03-07 | — | — | US | disclosed |
| US-20010039276-A1 | Phenethyl-thiourea compounds and use | PARKER HUGHES INSTITUTE (US) | 2001-11-08 | — | — | US | disclosed |
| US-20010003748-A1 | Phenethyl-thiourea compounds and use | PARKER HUGHES INSTITUTE (US) | 2001-06-14 | — | — | US | disclosed |
| US-6207688-B1 | TREATING MULTI-DRUG RESISTANT, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE RESISTANT, AND THERAPY NAIVE HIV INFECTION BY ADMINISTERING PHENETHYL-THIOUREA DERIVATIVE | PARKER HUGHES INSTITUTE | 2001-03-27 | — | — | US | disclosed |
| WO-2000078721-A1 | PHENETYL-THIOUREA COMPOUNDS FOR TREATING HIV INFECTIONS | PARKER HUGHES INSTITUTE (US) | 2000-12-28 | — | — | WO | disclosed |
| CN-1264384-A | Fused 1,2,4-thiadiazine derivatives, their preparation method and use | NOVO NORDISK AS (DK) | 2000-08-23 | — | — | CN | disclosed |
| US-5198454-A | Use of OB-104 to treat ocular inflammation | TEXAS A&M UNIVERSITY SYSTEM (US) | 1993-03-30 | — | — | US | disclosed |
| US-4177072-A | HYDROPHILIC AND OLEOPHILIC AREAS | FUJI PHOTO FILM CO., LTD. (JP) | 1979-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028837-A1 | Phenethyl-thiourea compounds and use | TPMT, PNMT, PNP | MAPT 214/4885HDAC3 4218/4885HDAC4 2833/4885 |
| US-20010039276-A1 | Phenethyl-thiourea compounds and use | TPMT, PNMT, PNP | MAPT 214/4885HDAC3 4218/4885HDAC4 2833/4885 |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | MAPT 680/4885HDAC3 1287/4885HDAC4 1085/4885 |
| US-20010003748-A1 | Phenethyl-thiourea compounds and use | TPMT, PNMT, PNP | MAPT 214/4885HDAC3 4218/4885HDAC4 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.